Related Experiment Video

Updated: Apr 30, 2026

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

5.5K

[Characteristics of antibiotic therapy in neonates with polyorgan insufficiency]

E N Serebriakova, D K Volosnikov, G A Glazyrina

    Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]
    |April 25, 2014
    PubMed

    Insights

    Polyorgan insufficiency (POI) is a leading cause of death in intensive care unit (ISU) patients, especially newborns. Optimizing antibacterial therapy for neonates with POI is crucial for improving outcomes.

    Area of Science:

    • Neonatal intensive care
    • Pediatric critical care
    • Infectious disease in neonates

    Context:

    • Polyorgan insufficiency (POI) is the primary cause of mortality in intensive care unit (ISU) patients, with newborns experiencing the highest rates of morbidity and mortality.
    • While antibacterial therapy is standard for suspected infections in neonatology, prolonged use poses risks to newborn infants.

    Purpose:

    • To investigate the specific characteristics and challenges of antibacterial therapy in newborn infants diagnosed with polyorgan insufficiency (POI).

    Summary:

    • This study analyzed antibacterial therapy in 453 newborn infants with POI, finding 100% received treatment.
    • III and IV generation cephalosporins and aminoglycosides were the most common drugs. Therapy was more intensive and prolonged in severe cases, particularly for infants weighing under 1500g.
    • Discontinuation of antibacterial therapy was based on the recovery of organ function, highlighting the need for optimized treatment protocols.

    Impact:

    • The findings underscore the necessity for refining antibacterial treatment strategies in neonates with POI to mitigate risks and improve survival rates.
    • This research provides critical insights for clinicians managing critically ill newborns, guiding more effective and safer therapeutic interventions.

    More Related Videos

    Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates08:32

    Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates

    Published on: February 17, 2023

    1.7K
    Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses11:17

    Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

    Published on: August 30, 2018

    11.6K

    Related Concept Videos

    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    408
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    967
    Acute Pyelonephritis II: Diagnostic Studies and Management01:28

    Acute Pyelonephritis II: Diagnostic Studies and Management

    Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
    842
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
    410
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
    554
    Pneumonia IV: Management01:28

    Pneumonia IV: Management

    The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
    Bacterial Pneumonia Treatment
    For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
    1.2K